ArticleDiabetes, obesity & metabolism2014
Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies.
Article in Diabetes, obesity & metabolism, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 51 citations in OpenAlex.
- Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial.Clinical drug investigation · 2015Trial
- Article
- Incretins and SGLT-2 inhibitors in diabetic patients with neuroendocrine tumors: current updates and future directions.Reviews in endocrine & metabolic disorders · 2025Review
- Incretin based therapy and pancreatic cancer: Realising the reality.World journal of gastroenterology · 2022Review
- Revisiting Regulators of Human β-cell Mass to Achieve β-cell-centric Approach Toward Type 2 Diabetes.Journal of the Endocrine Society · 2021Review
- Incretin-based therapy and pancreatitis: accumulating evidence and unresolved questions.Annals of translational medicine · 2018Article
- Effects of Linagliptin on PancreaticJournal of the Endocrine Society · 2017Article
- Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice.Endocrinology · 2017Article
- Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2016Article
- An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass.Diabetes & metabolism journal · 2016Review
- Human Islet Morphology Revisited: Human and Rodent Islets Are Not So Different After All.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2015Article
- Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic condition.Journal of translational medicine · 2015Article
- Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates.The American journal of pathology · 2015Article
- Balancing benefits and risks in patients receiving incretin-based therapies: focus on cardiovascular and pancreatic side effects.Drug safety · 2014Article
- Extra-pancreatic effects of incretin-based therapies.Endocrine · 2014Review
- Article
- Studying pancreatic risks caused by incretin-based therapies: is it a game? It's not a game!Journal of diabetes science and technology · 2014Article
- β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment.Diabetes care · 2014Review
- β-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment.The Journal of clinical endocrinology and metabolism · 2014Article
- Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2014Review
Corrections and comments
- Comment on
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
A recently published study by Butler et al. concluded that incretin treatment had adverse effects on the human type 2 diabetic pancreas including 'a marked expansion of the exocrine and endocrine pancreatic compartments, the former being accompanied by increased proliferation and dysplasia and the latter by α-cell hyperplasia with the potential for evolution into neuroendocrine tumours'. Incretin therapy has become widely used for type 2 diabetes, so these conclusions have instigated major concerns with regard to patient safety. We reassessed both the clinical case information and virtual microscopy images of the same 34 cases that were used in the Butler study as well as Network for Pancreatic Organ Donation (nPOD) cases that were not included. Whereas we would like to stress that it is important to investigate in depth any indication that incretin treatment may lead to inflammation or dysplasia in the pancreas, we find that the data presented in the Butler paper have serious methodological deficiencies that preclude any meaningful conclusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.